Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer
Oliver Sartor
Abstract
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival. See related article by Tolmeijer et al., p. 2835.
Topics & Concepts
Prostate cancerBiomarkerOncologyCirculating tumor DNAMedicineCancerInternal medicineBiologyGeneticsProstate Cancer Treatment and ResearchCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations